Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Revenue

Glenmark Pharmaceuticals had revenue of 40.18B INR in the quarter ending June 30, 2026, with 23.10% growth. This brings the company's revenue in the last twelve months to 177.37B, up 32.94% year-over-year. In the fiscal year ending March 31, 2026, Glenmark Pharmaceuticals had annual revenue of 170.43B with 27.53% growth.

• Revenue (ttm): 177.37B
• Revenue Growth: +32.94%
• P/S Ratio: 3.69
• Revenue / Employee: 10.47M
• Employees: 15,800
• Market Cap: 654.11B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	170.43B	36.79B	27.53%
Mar 31, 2025	133.63B	7.18B	5.68%
Mar 31, 2024	126.45B	9.90B	8.49%
Mar 31, 2023	116.56B	-6.49B	-5.28%
Mar 31, 2022	123.05B	13.61B	12.44%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error